New prodrug strategy for targeted chemotherapies

submit enquiry
Targeted chemotherapy © iStockphoto
Targeted chemotherapy © iStockphoto

University: University of Edinburgh

Sector(s): Healthcare & Pharmaceuticals, Chemical, Life Sciences

About Opportunity:

This new approach converts chemotherapy agents into prodrugs, significantly reducing systemic toxicity, and enabling local activation only at tumour sites where a specific catalyst, palladium, has been implanted. This offers the opportunity to significantly expand the therapeutic window for potent cytotoxics and expand treatment options for aggressive tumours, such as glioblastoma.

The Challenge

An important challenge limiting the efficacy of cancer chemotherapy drugs is their toxicity to healthy normal tissue. The significant side effect profile that many of these compounds have limits the effective doses that can be administered. One means to overcome this limitation is through a targeted pro-drug approach where the active form of the drug is a masked so that it is biologically inert and is activated to its toxic form only at the site of tumour. To achieve this, the prodrug form needs to have negligible pharmacological properties, but be readily cleavable in the presence of a suitable safe biologically inert catalyst present at the tumour site.

Technology

University of Edinburgh researchers have developed a method for generating a class of prodrugs that meet these criteria. The compounds are masked using a novel N-propargylation strategy that eliminates their cytotoxic properties. These prodrugs are readily activated in the presence of palladium, Pd(0), which rapidly catalyses the removal of the propargyl moiety and release of the fully active parent drug. By implanting an appropriate palladium source at the tumour site spatially controlled activation is achieved.

Exemplification Data

Significant in vitro data showing the applicability of this approach: prodrug versions of 5- fluorouracil and floxuridine that are stable and non-toxic; rapid activation in the presence of Pd(0); significant in vitro toxicity in a panel of cancer cell lines; ex vivo validation of Floxuridine prodrug in prostate cancer explants.

Development Status

Proof of principal data

Key Benefits:

  • Repeated systemic administration is possible
  • Cytotoxic activity is achieved locally only at tumour site
  • Expands arsenal of chemotherapy agents available to treat tumours such as glioblastoma multiforme

Applications:

  • Generation of prodrugs from heterocyclic compounds
  • Oncology drug discovery and delivery
  • Targeted therapeutics

IP Status:

Patent application (WO/2014/202994) covering methods, compounds and their uses.

Publications:

  • Nature Communications (2014) (5) 3277
  • Sci. Rep. (2015) 19 (5):9329

The University of Edinburgh is seeking commercial partners to license this technology and/or collaborate on further development of the technology for commercial use.

Enquiry

Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities


Register Now for University Technology.com Alerts


Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.